Results 181 to 190 of about 1,655,142 (283)

Hurdles to open access publishing faced by authors: a scoping literature review from 2004 to 2023. [PDF]

R Soc Open Sci
Kaliuzhna N, Aydin Z, Müller P, Hauschke C.   +3 more
europepmc   +1 more source

Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year. [PDF]

BMJ Open, 2021
Ellingson MK, Shi X, Skydel JJ, Nyhan K, Lehman R, Ross JS, Wallach JD.   +6 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Economic and geographical disparities in global contribution to open access publishing in anaesthesiology: A bibliometric analysis. [PDF]

Indian J Anaesth
Slawka E, Guerra-Londono JJ, Hicklen RS, Solanki SL, Cukierman D, Tian J, Cata JP.   +6 more
europepmc   +1 more source

Re: Jena R, Sharma AP, Madhavan K, Sridhar AN, Parmar K, Shrivastava N. What should urologists know about pseudojournals and open access publishing? A narrative review of the literature. Indian J Urol 2022;38:184-90. [PDF]

Indian J Urol, 2023
Kumar N, Tillu ND, Jain S.
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

High-Impact Open Access Scientific Publishing

Paidéia (Ribeirão Preto), 2015
Manoel Antônio dos Santos
doaj   +1 more source

Looking back at 20 years of Open Access publishing at Nucleic Acids Research. [PDF]

Nucleic Acids Res
Roberts R.
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Open-access publishing in times of crises: The future of scientific success lies in accessibility for all

Marshall Journal of Medicine, 2021
Darshana Shah
doaj   +1 more source